RecruitingPhase 2Drug trialProspective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLCThis is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.